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We examined the relationship between Short Physical Performance Battery (SPPB) and clinical and 
laboratory factors and the effect of sarcopenia and sarcopenic obesity (SO) on clinical and laboratory 
factors for cardiovascular disease (CVD) inpatients. CVD male (n = 318) and female (n = 172) inpatients 
were recruited. A stepwise multiple-regression analysis was performed to predict total SPPB scores 
and assess clinical and laboratory factors (physical characteristics, functional and morphological 
assessments, etc.). Each test outcome were compared among sarcopenia, SO and non-sarcopenic 
groups. To predict total SPPB scores, the predicted handgrip, Controlling Nutritional Status score, 
% body fat, anterior mid-thigh muscle thickness, standing height and systolic blood pressure were 
calculated for males and anterior mid-thigh MTH, BMI, knee extension and fat mass were calculated 
for females. There were no differences in blood pressure, total SPPB scores and functional assessments 
between sarcopenia and SO groups for CVD male and female inpatients. In conclusion, the physical 
performance of CVD inpatients can be predicted by nutritional, functional, clinical and anthropometric 
variables, regardless the gender and the presence of sarcopenia. Furthermore, the presence of 
sarcopenia has a negative effect on the clinical and laboratory factors, but there is a difference in impact 
between sarcopenia and SO regardless the gender.
Cardiovascular disease (CVD) is a major contributor to the global burden of diseases1,2. In addition, CVD (heart 
failure and stroke, etc.) often causes disuse muscle atrophy in the acute and subacute phases, which increases the 
likelihood of wheelchair or bedridden state in the chronic phase3–5. Consequently, the progression of muscle atro-
phy in lower extremity function in CVD inpatients leads to a high need for medical and nursing care.
The Short Physical Performance Battery (SPPB), a brief performance battery based on a timed short distance 
walk, repeated chair stands, and a set of balance tests, is a validated assessment tool for measuring lower extremity 
function that is widely used in both clinical and research settings6,7. This means of assessment offers relative ease 
of use, perceived potential for implementation in clinical practice, and a good relationship with physical activity 
levels and walking disability in a variety of patients or older adults. In fact, a recent study demonstrated that the 
SPPB is an effective assessment tool for strength and lower extremity morphological evaluation for middle-aged 
and older cardiovascular disease patients (mixed inpatients and outpatients)8. It has also been found to predict 
mortality, hospitalization rate, and a variety of comorbid disease conditions7. However, a previous study of older 
inpatients reported that approximately 88% were malnourished and approximately 12% were at risk for malnu-
trition9. In a SPPB study for older inpatients, therefore, it is particularly necessary to carry out a comprehensive 
analysis (muscle strength, muscle morphology, nutrition status and body composition, etc.).
The assessment of body composition is commonly performed by quantifying fat mass and fat-free mass (e.g., 
skeletal muscle mass) components. These components are often utilized to assess the risk for adverse health out-
comes in a variety of conditions10. In addition, some studies have demonstrated that sarcopenia, the age-related 
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loss of skeletal muscle mass and strength11, and also obesity, an increase in fat mass12, increase the risk of mortal-
ity. Recently, sarcopenia is found to often co-occur with an increase in fat mass, termed sarcopenic obesity, which 
may carry the cumulative risk derived from each of the two individual body composition factors13,14. Accordingly, 
recent clinical studies have focused on health outcomes in sarcopenic obesity as well as sarcopenia15,16.
Thus, the purpose of this study was to examine the relationship between the SPPB and clinical and laboratory 
factors and the effect of sarcopenia and sarcopenic obesity on clinical and laboratory factors in CVD inpatients.
Results
The physical characteristics and clinical data. Age and % body fat were greater (P < 0.01) in females than 
in males, but standing height, body weight, and BMI were greater (p < 0.01) in males than in females (Table 1). SPPB, 
functional and morphological assessments are shown in Table 2. Some subjects failed to perform the chair stand test 
(19 males and 17 females) and gait test (1 male and 2 females). In addition, BIA (InBody device) was contraindicated 
for 11 males and 15 females. Anterior-mid MTH correlated positively with SMI of males (r = 0.685, p < 0.0001) and 
females (r = 0.608, P < 0.0001) and the whole sample (r = 0.691, p < 0.0001) (Fig. 1). Total SPPB score, functional, 
and morphological assessments were greater (p < 0.01) in males than in females. Unlike the sarcopenia, the propor-
tion of SO assessments for CVD patients was larger in females than in males (Fig. 2). In both CVD male and female 
inpatients, body weight, BMI, % body fat, and body fat mass were greater (p < 0.05) in SO than in sarcopenia. There 
were no differences (p > 0.05) in systolic and diastolic blood pressures, CRP, total SPPB scores and functional assess-
ments between the sarcopenia and the SO groups for CVD male and female inpatients (Table 3).
The relationship between SPPB and clinical and laboratory factors. To predict total SPPB scores, the 
predicted handgrip, CONUT, % body fat, anterior mid-thigh MTH, standing height and diastolic BP were calcu-
lated for males (total SPPB scores = 0.101 × handgrip − 0.199 × CONUT − 0.110 × % body fat + 0.782 × anterior 
mid-thigh MTH −0.072 × standing height + 0.029 × diastolic BP + 17.836) (n = 318, R2 = 0.523, p < 0.05) and anterior 
mid-thigh MTH, BMI, knee extension and fat mass were calculated for females (total SPPB scores = 1.902 × anterior 
mid-thigh MTH −0.627 × BMI + 0.157 × knee extension + 0.223 × fat mass + 10.940) (n = 172, R2 = 0.411, p < 0.05).
Discussion
The main findings of this study were as follows: First, anterior mid-thigh MTH can predict total SPPB scores for 
both CVD male and female inpatients. Second, non-sarcopenic group was superior for morphological and func-
tional assessments compared with sarcopenia and SO groups, and there were slightly differences between the two 
groups in assessment for CVD male and female inpatients.
Male (n = 318) Range Female (n = 172) Range
Age, years 68.4 (13.0) 22–90 75.0 (10.8)** 40–96
Standing height, m 164.6 (6.5)** 147–190 149.0 (7.0) 127–173
Body weight, kg 64.0 (12.8)** 36.9–108.0 50.1 (10.7) 29.5–93.8
BMI, kg/m2 23.6 (3.9) ** 13.8–36.5 22.3 (4.2) 14.1–37.9
% body fat 26.8 (7.7) 6.7–49.0 33.3 (10.1)** 8.0–53.6
Fat mass, kg 17.8 (7.6) 2.7–50.6 17.5 (8.0) 2.4–50.0
Systolic BP, mmHg 115 (16) 73–159 112 (16) 77–164
Diastolic BP, mmHg 65 (11) 40–96 64 (11) 35–93
CONUT score, unit 3.6 (2.8) 0–12 3.7 (2.5) 0–10
BNP, pg/mL 536 (703) 3–3843 553 (812) 7–5015
Specific diseases, n
Cardiovascular surgery patients, n
 CABG and/or non-CABG 86 — 37 —
 Aortic dissection and aneurysm 42 — 21 —
 ASO 9 — 3 —
 Others (VAD, ASD, et al.) 3 — 4 —
 TAVI 1 — 11 —
 Patients with internal cardiovascular diseases
 CHF 95 — 65 —
 CHD (AMI, ACS, PCI et al.) 79 — 27 —
 Others (PE etc.) 3 — 4 —
Table 1. The physical characteristics and clinical data. Data are given as mean (standard deviation). BMI, Body 
mass index. BNP, brain natriuretic peptide. BP, blood pressure. CONUT, Controlling Nutrition Status. SMI, 
skeletal muscle mass index. CABG, coronary artery bypass grafting. Non-CABG, heart valve replacement and 
repair. VAD, ventricular assist device. VSD, ventricular septal defect. ASO, ateriosclerosis obliterans. TAVI, 
tanscatheter aortic valve implantation. CHF, congestive heart failure. CHD, coronary heart disease. AMI, 
acute myocardial infarction. ACS, acute coronary syndrome. PCI, percutaneous coronary intervention. PE, 
pulmonary embolism. **p < 0.01, Male vs. Female.
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A previous study reported that impaired mobility was reflected by total SPPB scores of less than 10 and those with 
total SPPB scores of 7–9 were 1.6 to 1.8 times more likely to become disabled17,18. In addition, total SPPB scores of 4–6 
were 4.2 to 4.9 times more likely to have disability in the activities of daily living or mobility-related disability at 4 years. 
Therefore, the SPPB assessment was established as a disability evaluation for older adults, healthy elderly and for some 
disability conditions6,19,20. In this study, the average score (9.7 for males and 8.2 for females) and the distribution (0–3: 
6% and 5%, 4–6: 20% and 20%, 7–9: 31% and 25%, 10–12: 43% and 49% for male and female inpatients, respectively) 
of total SPPB scores were almost the same as the previous CVD study (score 9.0; distribution 0–3: 0%, 4–6: 17%, 7–9: 
25%, 10–12: 50% for mixed male and female inpatients)8. Although a previous study investigated whether SPPB can 
be validated as an assessment tool for muscle strength and morphology in various physical condition (12 inpatients, 
12 outpatients and 12 healthy subjects), a stepwise multiple-regression analysis could be applied to the predictor ante-
rior mid-thigh muscle thickness to predict total SPPB scores for CVD in both studies. Taken together, these results 
suggested that the total SPPB scores could be evaluated by morphological assessment in knee extensor muscles for 
middle-aged and older adults regardless of male/female and CVD outpatient/inpatient.
In general, SMI assessed by BIA and DXA is used extensively in sarcopenia criteria as in European Working 
Group on Sarcopenia in Older People (EWGSOP)21 and AWGS22. However, we could not measure the SMI for 
26 inpatients (11 males and 15 females), because individuals with cardiac pacemakers are generally regarded as 
a contraindication to BIA, DXA and MRI measurements. In contrast, MTH assessed by ultrasound is also used 
as a muscle mass in clinical medicine and sports science, and there is no contraindication even for individuals 
Male(n =318) Range Female (n = 172) Range
SPPB score
 Balance test 3.6 (0.8)** 0–4 3.1 (1.2) 0–4
 Gait test 3.4 (0.9)** 0–4 3.0 (1.0) 1–4
 Chair stand test 2.7 (1.4)** 0–4 2.0 (1.4) 0–4
 Total SPPB 9.7 (2.7)** 0–12 8.2 (3.0) 1–12
Functional assessment
 Handgrip, kg 28.3 (8.5)** 10.4–52.5 15.2 (4.6) 0.0–28.3
 Knee extension, kg 25.6 (12.1)** 5.2–60.2 13.7 (6.7) 2.0–45.4
Morphological assessment
 Fat-free mass, kg 46.2 (7.9)** 17.6–71.1 32.5 (5.3) 17.8–53.9
 Skeletal muscle mass, kg 24.9 (4.7)** 15.3–39.1 16.8 (3.5) 11.1–37.0
 SMI, kg/m2 7.08 (1.17)** 4.48–11.40 5.30 (1.00) 3.25–8.11
 Mid-thigh girth, cm 45.4 (5.9)** 30.1–61.0 42.3 (6.2) 29.0–62.4
 Anterior mid-thigh MTH, cm 3.62 (0.98)** 1.36–6.72 3.00 (0.73) 1.24–5.17
 Posterior mid-thigh MTH, cm 5.58 (1.07)** 2.58–8.62 4.91 (0.99) 2.02–8.75
Table 2. Short physical performance battery (SPPB), functional, and morphological assessments. Data are 
given as mean (standard deviation). MTH, muscle thickness. SMI, skeletal muscle mass index. **p < 0.01, Male 
vs. Female.
Figure 1. Relationships between anterior-mid muscle thickness (MTH) and skeletal muscle index (SMI) of 
CVD male and female inpatients.
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with cardiac pacemakers. In addition, there was a high correlation coefficient (r = 0.685, p < 0.0001 for males and 
r = 0.608, p < 0.0001 for females) between anterior mid-thigh MTH (mainly dependent on quadriceps muscles) 
and SMI in this study (Fig. 1). Furthermore, previous studies revealed that sarcopenia is muscle specific and 
greater quadriceps muscle loss was found in older adults23,24. These results indicated that additional research into 
anterior mid-thigh MTH assessed by ultrasound on sarcopenia criteria is worthy of attention.
There was little relationship between the total SPPB scores and CONUT score in this study. The CONUT score 
was 3.6 for male and 3.7 for female inpatients and the prevalence of malnutrition (mild [2–4]: 40% and 34%; 
moderate [5–8]: 26% and 37%; severe [9–12]: 7% and 4% for male and female, respectively) was 73–75%. These 
Figure 2. Diagnostic algorithm for Sarcopenia and Sarcopenic Obesity of CVD male (a) and female (b) 
inpatients.
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results were similar to those in a previously reported studies in inpatients with acute or chronic heart failure (78% 
for AHF and 60–69% for CHF)25,26. This appears that prognostic value of malnutrition assessed by CONUT score 
may not be a decisive factor in the assessment of SPPB score for CVD male inpatients.
A previous study reported that SO is associated with all-cause mortality and also with greater CVD mortality, 
largely because of their association with blood pressure, blood lipids and inflammation27. In this study, there was 
no difference in blood pressures, inflammation, and functional assessment between the sarcopenia and the SO 
groups for CVD male and female inpatients. Additionally, the CONUT score and the knee extensor muscle mor-
phology for the SO group were either equal to or surpassed those of the sarcopenia group. Therefore, it is highly 
likely that the SO group induced greater cardiovascular mortality and all-cause mortality was independent of 
functional assessment, as well as blood pressure and inflammation, although the mortality for the sarcopenia and 
the SO groups was not investigated. Additional research into these issues is needed.
The present study has some limitations. First, it was very difficult to evaluate the various assessments within 
the same hospital admission for the inpatients. Second, SPPB assessment could not be evaluated for severely 
impaired mobility patients because some subjects failed to perform the chair stand test (19 males and 17 females) 
and the gait test (1 male and 2 females). Third, some data were missing due to impossible measurement (method 
discussed above), sudden discharge from hospital, acute deterioration, contraindication and others for the inpa-
tients. Additional research into these issues is needed.
In conclusion, the physical performance of CVD inpatients can be predicted by nutritional, functional, clinical 
and anthropometric variables, regardless the gender and the presence of sarcopenia. Furthermore, the presence of 
sarcopenia has a negative effect on the clinical and laboratory factors, but there is a difference in impact between 
sarcopenia and SO regardless the gender.
Male (n = 141) Female (n = 98)
Sarcopenia SO NS Sarcopenia SO NS
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
n = 31 n = 36 n = 74 n = 21 n = 38 n = 39
Age, years 77.2 (6.5)## 79.0 (5.8)¶¶ 72.5 (6.0) 79.9 (8.0) # 79.3 (6.2)¶¶ 74.7 (6.4)
Systolic BP, mmHg 116 (16) 115 (14) 116 (18) 110 (18) 110 (16)¶ 120 (15)
Diastolic BP, mmHg 62 (13) 62 (12) 65 (10) 61 (11) 64 (9) 67 (10)
CRP, mg/dl 4.5 (6.3)*,## 2.8 (5.8) 1.6 (2.5) 1.8 (3.0) 1.5 (2.9) 1.3 (3.7)
BNP, pg/mL 802 (778)## 498 (644)¶ 362 (510) 690 (537)## 504 (563)¶ 269 (555)
CONUT score, unit 5.9 (2.7)*,## 4.0 (2.9) 2.9 (2.6) 3.8 (2.6) 3.5 (2.2) 2.8 (2.5)
SPPB score
 Balance test 3.5 (0.7) 3.3 (1.1)¶ 3.7 (0.8) 3.1 (0.9)## 2.8 (1.0)¶¶ 3.4 (0.8)
 Gait test 2.9 (1.0)## 2.8 (0.9)¶¶ 3.8 (0.6) 2.8 (1.0) # 2.8 (1.1)¶ 3.4 (0.8)
 Chair stand test 1.7 (1.3)## 1.9 (1.5)¶¶ 3.3 (0.9) 1.4 (1.2)## 1.8 (1.3)¶ 2.5 (1.4)
 Total SPPB 8.2 (2.1)## 7.9 (2.5)¶¶ 10.8 (1.9) 7.4 (2.4)## 7.6 (3.1)¶ 9.4 (2.6)
Functional assessment
 Handgrip, kg 20.9 (4.6)## 20.7 (4.7)¶¶ 31.2 (6.4) 12.7 (4.2)## 13.3 (3.2)¶¶ 18.3 (3.8)
 Knee extension, kg 17.6 (6.5)## 16.4 (6.6)¶¶ 28.7 (11.5) 8.7 (3.5)**,## 12.3 (5.4)¶¶ 17.7 (5.9)
Morphological assessment
 Height, m 1.61 (0.05)¶¶ 1.60 (0.06)¶¶ 1.64 (0.05) 1.48 (0.07) 1.46 (0.07)¶¶ 1.50 (0.05)
 Body weight, kg 53.0 (7.0)##,** 60.0 (5.8)¶¶ 65.8 (9.4) 40.9 (7.6)**,## 48.9 (6.6)¶¶ 55.3 (8.8)
 BMI, kg/m2 20.2 (2.5)##,** 23.2 (2.3) 24.1 (3.2) 17.9 (2.8)**,## 22.8 (3.3)¶ 24.1 (3.5)
 % body fat 19.7 (3.7)##,** 32.8 (4.4)¶¶ 27.4 (6.1) 20.3 (6.7)**,## 39.3 (6.5)¶ 35.5 (7.9)
 Fat-free mass, kg 40.6 (3.9)*,## 38.2 (4.9)¶¶ 47.3 (5.9) 30.2 (4.8)## 28.9 (3.3)¶¶ 35.0 (3.6)
 Body fat mass, kg 10.3 (2.6)##,** 19.1 (3.7) 18.2 (5.6) 9.5 (6.0)##,** 19.2 (5.3) 20.0 (7.0)
 Skeletal MM, kg 21.2 (2.4)## 20.4 (2.0)¶¶ 25.6 (3.4) 15.3 (2.2)## 14.6 (1.9)¶¶ 18.1 (2.0)
 SMI, kg/m2 6.02 (0.67)## 6.09 (0.53)¶¶ 7.50 (1.05) 4.62 (0.60)## 4.72 (0.67)¶¶ 6.09 (0.73)
 Mid-thigh girth, cm 39.2 (3.0)**,## 42.3 (3.5)¶¶ 46.0 (4.0) 36.9 (6.2)*,## 41.5 (3.6)¶¶ 46.1 (5.0)
 Anterior MTH, cm 2.67 (0.54)*,## 2.97 (0.67)¶¶ 3.74 (0.71) 2.46 (0.52)## 2.80 (0.70)¶¶ 3.35 (0.58)
 Posterior MTH, cm 4.91 (0.94)## 5.10 (1.04)¶¶ 5.80 (0.89) 4.63 (0.73)## 4.78 (1.26)¶¶ 5.27 (0.78)
Table 3. Comparison among Sarcopenia, Sarcopenic Obesity (SO) and non-sarcopenic (NS) groups in 
cardiovascular disease male and female inpatients (≥65 years). Data are given as mean (standard deviation). 
BNP, brain natriuretic peptide. BP, blood pressure. CONUT, Controlling Nutrition Status. CRP, C-reactive 
protein. MM, muscle mass, MTH, mid-thigh muscle thickness. SMI, skeletal muscle mass index. **p < 0.01, 
*p < 0.05, Sarcopenia vs. SO groups. ##p < 0.01, #p < 0.05, Sarcopenia vs. Non-sarcopenic groups. ¶¶p < 0.01, 
¶p < 0.05, SO vs. Non-sarcopenic groups.
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Methods
Participants. Four hundred-ninety (aged 22 to 96 years) male (n = 318) and female (n = 172) inpatients with car-
diovascular disease volunteered to participate in the study and were selected according to the exclusion criteria (i.e. 
cerebrovascular disease patients and those undergoing arthroscopic joint surgery) (Table 1). In addition, volunteers 
who suffered from a chronic disease such as severe orthopedic disorders, or cognitive dysfunction were excluded from 
the study. All participants had undergone complete chemistry and hematologic evaluation and were informed of the 
risks associated with involvement in the study and signed an informed consent document before participation. All par-
ticipants were recruited through oral communications in the Dokkyo Medical University Hospital. The principles of the 
World Medical Association Declaration of Helsinki and the American College of Sports Medicine Guidelines for Use of 
Human Subjects were adopted in this study. The study was approved by the Ethics Committee of the Dokkyo Medical 
University, and informed assent consent were obtained from the participants. All data were analyzed by the same author 
(a specialist in exercise physiology research for more than 15 years), who was blinded to all of the measurements.
Short physical performance battery. Participants performed the Short Physical Performance Battery (SPPB) 
according to the National Institute on Aging protocol. The tests were performed in the following sequence: a) standing 
balance tests, b) gait test (4 m), and c) chair stand test (5 repetitions). The standing balance portion requires participants 
to maintain, for 10 seconds each, stances with their feet placed side by side, semi-tandem, and in tandem. The scores 
ranged from 0 to 4 (maximum performance). The gait test measured the time needed to walk 4 m at a typical pace. The 
chair stand required participants to rise from a steel chair (0.40 m height and 0.30 m depth) with their arms across their 
chest, five times. Categorical scores (range: 0 to 4) for both the gait and the chair stand tests were based on timed quar-
tiles established previously in a large population. Individuals who were unable to complete either the 4 m gait task or 
the 5 repetitions chair stand test received a score of 0. The sum of the three components comprised the final SPPB score, 
with a possible range from 0 to 12. A score of 12 indicated the highest degree of lower extremity function6,28.
Maximum voluntary isometric contraction. Maximum voluntary isometric contraction (MVIC) 
of the handgrip was determined using a factory-calibrated hand dynamometer (TKK 5401, TAKEI Scientific 
Instruments Co., Ltd., Tokyo, Japan). All of the subjects were instructed to maintain an upright standing position, 
arms at their side, holding the dynamometer in the right hand with the arm at a right angle and the elbow held 
at the side of the body. The size of the dynamometer handle was set so that it felt comfortable to the subject while 
squeezing the grip. Each subject underwent 2 trials, and the best value of 2 trials was used for analysis.
MVIC of the knee extensors was determined using a digital handheld dynamometer (μTas MT-1, ANIMA Co., 
Ltd., Tokyo, Japan)29. The dynamometer pad used was 55 × 55 mm, and its front side was curved to fit the shape of 
the area of the extremity to be measured. Subjects were seated in a hard chair with their knees flexed 90° and their 
arms on their thighs. The dynamometer was placed perpendicular to the leg just above the malleoli. During all 
tests, the dynamometer was kept stable by the examiner using both hands and the subject’s leg was fixed by a belt 
to keep the knee flexed at 90°. Subjects were told to push against the dynamometer by attempting to straighten 
their leg. They were asked to build force gradually to a maximum voluntary effort. Each subject performed 2 trials 
with an interval of at least 2 min between the trials. The highest score was adopted for the individual data.
Skeletal muscle index. The multi-frequency bioelectrical impedance analyzer (BIA), InBody S10 Biospace 
device (Biospacte Co., Ltd., Korea/Model JMW140) was used according to the manufacturer’s guidelines. BIA estimates 
body composition using the difference of conductivity of the various tissues based on the differences in their biological 
characteristics. Conductivity is proportional to water content, and more specifically to electrolytes, and it decreases as 
the cell approaches a perfect spherical shape. Adipose tissue is composed of round shaped cells and contains relatively 
little water compared to other tissues like muscle; therefore, conductivity isdecreased as body fat increases. In practice, 
electrodes are placed at 8 precise tactile-points of the body to achieve a multi-segmental frequency analysis. A total of 30 
impedance measurements were obtained using 6 different frequencies (1, 5, 50, 250, 500, and 1000 kHz) at the 5 follow-
ing segments of the body: right and left arms, trunk, right and left legs30. The measurements were carried out while the 
subjects rested quietly in the supine position, with their elbows extended and relaxed along their trunk. Percent body 
fat, fat-free mass and skeletal muscle mass were recorded. Also, skeletal muscle index (SMI; AMM/height2, kg/m2) was 
measured as the sum of lean soft tissue of the two upper limbs and two lower limbs (appendicular muscle mass: AMM).
Muscle thickness. After thigh length measurements using anatomic landmarks, all measurement sites were 
marked with a marker pen and then mid-thigh (at 50% between the lateral condyle of the femur and the greater 
trochanter) girth and mid-thigh muscle thickness were measured using a tape measure on the right side of the 
body31. Ultrasound evaluation of muscle thickness (MTH) was performed by using a real-time linear electronic 
scanner with a 10.0-MHz scanning head and Ultrasound Probe (L4–12t-RS Probe, GE Healthcare Japan) by using 
LOGIQ e ultrasound (GE Healthcare Japan). The scanning head was coated with a water-soluble transmission 
gel to provide acoustic contact without depressing the dermal surface. The subcutaneous adipose tissue-muscle 
interface and the muscle-bone interface were identified from the ultrasonic image. The perpendicular distance 
from the adipose tissue-muscle interface to the muscle-bone interface was considered to represent MTH. Briefly, 
the measurements were carried out while the subjects stood with their elbows extended and relaxed31.
Controlling nutritional status score. The Controlling Nutritional Status (CONUT) score, which is cal-
culated by the serum albumin concentration (range: 0 to 6), the total peripheral lymphocyte count (range: 0 to 
3), and the total cholesterol concentration (range: 0 to 3), was developed as a screening tool for early detection 
of poor nutritional status. The sum of the three components comprised the final CONUT score, with a possible 
range from 0 to 12. A score of 12 indicated the poorest nutritional status32. Use of the CONUT score has advan-
tages, such as simplicity and cost effectiveness32,33.
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Definition of sarcopenia and sarcopenic obesity. In this study, sarcopenia was defined according to the 
Asian Working Group for Sarcopenia (AWGS)22 criteria (age, ≥65 years; handgrip, <26 kg for males and <18 kg 
for females; gait speed, ≤0.8 m/sec; SMI, <7.0 kg/m2 for males and <5.7 kg/m2 for females). Sarcopenia obesity 
(SO) was considered to be the combination of sarcopenia and obesity (% body fat >25% for males and >30% for 
females)34–37.
Statistical analyses. Results are expressed as mean ± standard deviation for all variables. All data were 
analyzed using JMP v.12.0 for Mac (SAS Institute Inc., Tokyo, Japan). Pearson product correlations of total 
SPPB scores and variable factors were also statistically quantified. When the data were not normally distrib-
uted, non-parametric statistical analysis (Wilcoxon signed rank test) was used to identify differences in sar-
copenia, SO and non-sarcopenic groups. Since the value of events per variable = 10 seems most prudent for 
regression analysis38, 17 variable factors were acceptably for both genders (n = 318 and 172 for male and female 
inpatients, respectively). In addition, the variance inflation factor (VIF) were used to determine the degree of 
multi-collinearity of the i-th independent variable with other independent variables for all hierarchal regression 
models39. Multi-collinearity between variables was defined as a VIF ≥ 10, and fat free-mass was excepted for 
male in this study. Based on the result of VIF, a stepwise multiple-regression analysis (method of increasing and 
decreasing the variables, criterion was set at p < 0.05) was performed to predict SPPB scores and variable factors 
(age, standing height, body weight, BMI, % body fat, systolic and diastolic blood pressures, resting heart rate, 
handgrip, knee extension, fat free-mass (used exclusively for female), skeletal muscle mass, SMI, mid-thigh girth, 
anterior and posterior mid-thigh muscle thickness and CONUT score). Consequently, the predicted variables, 
coefficients and intercept coefficients were automatically picked out by the JMP software. Statistical significance 
was set at p < 0.05.
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